A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies

Trial Profile

A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2013

At a glance

  • Drugs Alvocidib (Primary)
  • Indications Advanced breast cancer; Chronic lymphocytic leukaemia; Haematological malignancies; Head and neck cancer; Kaposi's sarcoma; Lymphoma; Malignant melanoma; Mantle-cell lymphoma; Mesothelioma; Multiple myeloma; Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 01 Nov 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
    • 15 Oct 2007 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top